Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cells

Immunology and Cell Biology

Volumn 93, Issue 1, 2015, Pages 77-85

  Pupovac, Aleta ^a,b   Geraghty, Nicholas J ^a,b   Watson, Debbie ^a,b   Sluyter, Ronald ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b ILLAWARRA HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; ADENOSINE TRIPHOSPHATE; BATIMASTAT; CD23 ANTIGEN; PURINERGIC P2X7 RECEPTOR; 3-(FORMYLHYDROXYAMINO)-2-(3-PHENYL-1-PROPYL)BUTANOIC ACID (2,2-DIMETHYL-1-METHYLCARBAMOYL-1-PROPYL)AMIDE; ADAM PROTEIN; ADAM10 PROTEIN, HUMAN; BENZOXAZOLE DERIVATIVE; DIPEPTIDE; FLUORESCENT DYE; HYDROXAMIC ACID; IMMUNOGLOBULIN E RECEPTOR; MEMBRANE PROTEIN; PHENYLALANINE; PROTEINASE INHIBITOR; PURINERGIC P2X RECEPTOR ANTAGONIST; QUINOLINE DERIVATIVE; SECRETASE; THIOPHENE DERIVATIVE; YO-PRO 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; LYMPHOCYTE ACTIVATION; METABOLISM; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SPLEEN;

MURINAE; MUS;

ADAM PROTEINS; ADENOSINE TRIPHOSPHATE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; B-LYMPHOCYTES; BENZOXAZOLES; DIPEPTIDES; FLUORESCENT DYES; GENE EXPRESSION REGULATION; HUMANS; HYDROXAMIC ACIDS; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; PHENYLALANINE; PRIMARY CELL CULTURE; PROTEASE INHIBITORS; PURINERGIC P2X RECEPTOR ANTAGONISTS; QUINOLINIUM COMPOUNDS; RECEPTORS, IGE; RECEPTORS, PURINERGIC P2X7; SIGNAL TRANSDUCTION; SPLEEN; THIOPHENES;

EID: 84920535295     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.69     Document Type: Article

References (53)

1. Acharya M, Borland G, Edkins AL, Maclellan LM, Matheson J, Ozanne BW et al. CD23/FcεRII: molecular multi-tasking. Clin Exp Immunol 2010; 162: 12-23.
2. Borland G, Edkins AL, Acharya M, Matheson J, White LJ, Allen JM et al. αvβ5 integrin sustains growth of human pre-B cells through an RGD-independent interaction with a basic domain of the CD23 protein. J Biol Chem 2007; 282: 27315-27326.
3. Liu YJ, Cairns JA, Holder MJ, Abbot SD, Jansen KU, Bonnefoy JY et al. Recombinant 25-kDa CD23 and interleukin 1α promote the survival of germinal center B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol 1991; 21: 1107-1114.
4. Mossalayi MD, Lecron JC, Dalloul AH, Sarfati M, Bertho JM, Hofstetter H et al. Soluble CD23 (FcεRII) and interleukin 1 synergistically induce early human thymocyte maturation. J Exp Med 1990; 171: 959-964.
5. Hermann P, Armant M, Brown E, Rubio M, Ishihara H, Ulrich D et al. The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23. J Cell Biol 1999; 144: 767-775.
6. Weskamp G, Ford JW, Sturgill J, Martin S, Docherty AJ, Swendeman S et al. ADAM10 is a principal 'sheddase' of the low-affinity immunoglobulin E receptor CD23. Nat Immunol 2006; 7: 1293-1298.
7. Lemieux GA, Blumenkron F, Yeung N, Zhou P, Williams J, Grammer AC et al. The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10. J Biol Chem 2007; 282: 14836-14844.
8. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-837.
9. Bartlett R, Stokes L, Sluyter R. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol Rev 2014; 66: 638-675.
10. Cankurtaran-Sayar S, Sayar K, Ugur M. P2X7 receptor activates multiple selective dyepermeation pathways in RAW 264.7 and human embryonic kidney 293 cells. Mol Pharmacol 2009; 76: 1323-1332.
11. Farrell AW, Gadeock S, Pupovac A, Wang B, Jalilian I, Ranson M et al. P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells. Biochim Biophys Acta 2010; 1800: 1173-1182.
12. Gu B, Bendall LJ, Wiley JS. Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 1998; 92: 946-951.
13. Sluyter R, Wiley JS. Extracellular adenosine 5'-triphosphate induces a loss of CD23 from human dendritic cells via activation of P2X7 receptors. Int Immunol 2002; 14: 1415-1421.
14. Georgiou JG, Skarratt KK, Fuller SJ, Martin CJ, Christopherson RI, Wiley JS et al. Human epidermal and monocyte-derived Langerhans cells express functional P2X receptors. J Invest Dermatol 2005; 125: 482-490.
15. Pupovac A, Foster CM, Sluyter R. Human P2X7 receptor activation induces the rapid shedding of CXCL16. Biochem Biophys Res Commun 2013; 432: 626-631.
16. Le Gall SM, Bobe P, Reiss K, Horiuchi K, Niu XD, Lundell D et al. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor α, L-selectin, and tumor necrosis factor α. Mol Biol Cell 2009; 20: 1785-1794.
17. Le Gall SM, Maretzky T, Issuree PD, Niu XD, Reiss K, Saftig P et al. ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci 2010; 123: 3913-3922.
18. Donnelly-Roberts DL, Namovic MT, Han P, Jarvis MF. Mammalian P2X7 receptor pharmacology: Comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol 2009; 157: 1203-1214.
19. Michel AD, Chambers LJ, Walter DS. Negative and positive allosteric modulators of the P2X7 receptor. Br J Pharmacol 2008; 153: 737-750.
20. Pupovac A, Stokes L, Sluyter R. CAY10593 inhibits the human P2X7 receptor independently of phospholipase D1 stimulation. Purinergic Signal 2013; 9: 609-619.
21. Gu BJ, Zhang WY, Bendall LJ, Chessell IP, Buell GN, Wiley JS. Expression of P2X7 purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X7 receptors. Am J Physiol Cell Physiol 2000; 279: C1189-C1197.
22. Bartlett R, Yerbury JJ, Sluyter R. P2X7 Receptor activation induces reactive oxygen species formation and cell death in murine EOC13 microglia. Mediators Inflamm 2013; 2013: 271813.
23. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH et al. Altered cytokine production in mice lacking P2X7 receptors. J Biol Chem 2001; 276: 125-132.
24. Tran JN, Pupovac A, Taylor RM, Wiley JS, Byrne SN, Sluyter R. Murine epidermal Langerhans cells and keratinocytes express functional P2X7 receptors. Exp Dermatol 2010; 19: e151-e157.
25. Plater-Zyberk C, Bonnefoy JY. Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo. Nat Med 1995; 1: 781-785.
26. Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM et al. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 2002; 168: 6436-6445.
27. Portales-Cervantes L, Nino-Moreno P, Salgado-Bustamante M, Garcia-Hernandez MH, Baranda-Candido L, Reynaga-Hernandez E et al. The His155Tyr (489C4T) single nucleotide polymorphism of P2RX7 gene confers an enhanced function of P2X7 receptor in immune cells from patients with rheumatoid arthritis. Cell Immunol 2012; 276: 168-175.
28. Masin M, Young C, Lim K, Barnes SJ, Xu XJ, Marschall V et al. Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: Reevaluation of P2X7 knockouts. Br J Pharmacol 2012; 165: 978-993.
29. Constantinescu P, Wang B, Kovacevic K, Jalilian I, Bosman GJ, Wiley JS et al. P2X7 receptor activation induces cell death and microparticle release in murine erythroleukemia cells. Biochim Biophys Acta 2010; 1798: 1797-1804.
30. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005; 114: 386-396.
31. Nicke A, Kuan YH, Masin M, Rettinger J, Marquez-Klaka B, Bender O et al. A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem 2009; 284: 25813-25822.
32. Schwarz N, Drouot L, Nicke A, Fliegert R, Boyer O, Guse AH et al. Alternative splicing of the N-terminal cytosolic and transmembrane domains of P2X7 controls gating of the ion channel by ADP-ribosylation. PLoS ONE 2012; 7: e41269.
33. Taylor SRJ, Gonzalez-Begne M, Sojka DK, Richardson JC, Sheardown SA, Harrison SM et al. Lymphocytes from P2X7-deficient mice exhibit enhanced P2X7 responses. J Leuk Biol 2009; 85: 978-986.
34. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53: 2087-2091.
35. Ludwig A, Hundhausen C, Lambert MH, Broadway N, Andrews RC, Bickett DM et al. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 2005; 8: 161-171.
36. Fourie AM, Coles F, Moreno V, Karlsson L. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem 2003; 278: 30469-30477.
37. Syberg S, Schwarz P, Petersen S, Steinberg TH, Jensen JE, Teilmann J et al. Association between P2X7 receptor polymorphisms and bone status in mice. J Osteoporos 2012; 2012: 637986.
38. Jackson L, Cady CT, Cambier JC. TLR4-mediated signaling induces MMP9-dependent cleavage of B cell surface CD23. J Immunol 2009; 183: 2585-2592.
39. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749-3752.
40. Lester S, Stokes L, Skarratt KK, Gu BJ, Sivils KL, Lessard CJ et al. Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjogren's syndrome. Arthritis Res Ther 2013; 15: R71.
41. Woods LT, Camden JM, Batek JM, Petris MJ, Erb L, Weisman GA. P2X7 receptor activation induces inflammatory responses in salivary gland epithelium. Am J Physiol Cell Physiol 2012; 303: C790-C801.
42. Baldini C, Rossi C, Ferro F, Santini E, Seccia V, Donati V et al. The P2X7 receptorinflammasome complex has a role in modulating the inflammatory response in primary Sjogren's syndrome. J Intern Med 2013; 274: 480-489.
43. Huissoon AP, Emery P, Bacon PA, Gordon J, Salmon M. Increased expression of CD23 in rheumatoid synovitis. Scand J Rheumatol 2000; 29: 154-159.
44. Ribbens C, Bonnet V, Kaiser MJ, Andre B, Kaye O, Franchimont N et al. Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 120: 194-199.
45. Bansal A, Roberts T, Hay EM, Kay R, Pumphrey RS, Wilson PB. Soluble CD23 levels are elevated in the serum of patients with primary Sjogren's syndrome and systemic lupus erythematosus. Clin Exp Immunol 1992; 89: 452-455.
46. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101: 273-281.
47. Bendaoud B, Pennec YL, Lelong A, Le Noac'h JF, Magadur G, Jouquan J et al. IgAcontaining immune complexes in the circulation of patients with primary Sjogren's syndrome. J Autoimmun 1991; 4: 177-184.
48. Philpott NJ, Turner AJC, Westby M, Marsh JCW, Gordon-Smith EC, Dalgleish AG et al. The use of 7-amino actinomycin D identifying apoptosis: Simplicity of use and broad spectrum of application compared with other techniques. Blood 1996; 87: 2244-2251.
49. Gu BJ, Zhang WY, Worthington RA, Sluyter R, Dao-Ung P, Petrou S et al. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 2001; 276: 11135-11142.
50. Tsukimoto M, Maehata M, Harada H, Ikari A, Takagi K, Degawa M. P2X7 receptordependent cell death is modulated during murine T cell maturation and mediated by dual signaling pathways. J Immunol 2006; 177: 2842-2850.
51. Schmid I, Uittenbogaart CH, Giorgi JV. A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry 1991; 12: 279-285.
52. Gadeock S, Pupovac A, Sluyter V, Spildrejorde M, Sluyter R. P2X7 receptor activation mediates organic cation uptake into human myeloid leukaemic KG-1 cells. Purinergic Signal 2012; 8: 669-676.
53. Spildrejorde M, Bartlett R, Stokes L, Jalilian I, Peranec M, Sluyter V et al. R270C polymorphism leads to loss of function of the canine P2X7 receptor. Physiol Genomics 2014; 46: 512-522.